Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study
Study limitation reported by the research below: “Part 2 is the only randomised, controlled portion of the study; Parts 1, 3, and 4 are open-label single-arm designs, which limits the strength of comparative conclusions across the full trial.”